If I recall correctly, the company that became ABBV licensed the drug to Progenics, from whom CytoDyn then acquired it. They’re both owed some measure of royalties.
It’s in the 10-Q/K, but I don’t have that in front of me. I’m sure someone else can or will look it up before I get back to the notes on my computer on Tuesday.
News 
Market Data 
Discover 
AI
